DexCom, Inc. DXCM recently announced that results from its CONNECT randomized controlled trial have been published in The New England Journal of Medicine. The study evaluated the benefits of its ...

The twiist Automated Insulin Delivery System is now available for adults with insulin-treated type 2 diabetes.

The company continues the European rollout of DBLG2 and prepares new features and expanded indications to simplify diabetes ...

For readers seeking more insight into food and activity habits, this Signos review examines glucose-monitoring features, ...

DexCom is transforming into the premium CGM provider with the lowest cost per patient-day and robust clinical evidence. Read ...

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal ...

Scientists tested a wearable blood sugar monitor on adults who weren't taking insulin. The results revealed a measurable ...

DexCom (DXCM) stock jumps as peer-reviewed data from a study for the G7 insulin pump in type 2 diabetes boost its Medicare coverage hopes.

With Twiist already available in Type 1 diabetes, Sequel has made the automated insulin delivery system available for the Type 2 population.

By Nancy Lapid Oct 15 (Reuters) - Hello Health Rounds readers! Today we highlight a study that found benefits of wearable glucose monitoring devices for all patients with diabetes, regardless of ...